CASTLE BIOSCIENCES, INC. Net Income (Loss) Available to Common Stockholders, Basic
CASTLE BIOSCIENCES, INC. (CSTL) reported Net Income (Loss) Available to Common Stockholders, Basic of -$4.89 million for the 3-month period ending 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2021-03-11
- CASTLE BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-12-31 was -$4.89M, a 337.91% decline year-over-year.
- CASTLE BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-09-30 was -$4.59M, a 182.79% decline year-over-year.
- CASTLE BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-06-30 was -$1.38M.
- CASTLE BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-03-31 was $570.00K.
- CASTLE BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for fiscal 2020 was -$10.28M, a 443.83% decline from fiscal 2019.
- CASTLE BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for fiscal 2019 was $2.99M.
- CASTLE BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for fiscal 2018 was -$10.16M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | -$4.89M 10-K · filed 2021-03-11 | -$9.48M derived: sum of 2 quarters · filed 2021-03-11 | -$10.85M derived: sum of 3 quarters · filed 2021-03-11 | -$10.28M 10-K · filed 2021-03-11 | |||
| 2020-09-30 | -$4.59M 10-K · filed 2021-03-11 | -$5.96M derived: sum of 2 quarters · filed 2021-03-11 | -$5.39M 10-Q · filed 2020-11-09 | -$3.34M derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2020-06-30 | -$1.38M 10-K · filed 2021-03-11 | -$806.00K 10-Q · filed 2020-08-10 | $1.25M derived: sum of 3 quarters · filed 2021-03-11 | $6.79M derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2020-03-31 | $570.00K 10-K · filed 2021-03-11 | $2.63M derived: sum of 2 quarters · filed 2021-03-11 | $8.17M derived: sum of 3 quarters · filed 2021-03-11 | $5.90M derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2019-12-31 | $2.06M 10-K · filed 2021-03-11 | $7.60M derived: sum of 2 quarters · filed 2021-03-11 | $5.33M derived: sum of 3 quarters · filed 2021-03-11 | $2.99M 10-K · filed 2021-03-11 | |||
| 2019-09-30 | $5.54M 10-K · filed 2021-03-11 | $5.54M 10-Q · filed 2019-11-12 | $3.28M derived: sum of 2 quarters · filed 2021-03-11 | $936.00K 10-Q · filed 2020-11-09 | $935.72K 10-Q · filed 2019-11-12 | $3.80M derived: sum of 4 quarters · filed 2021-03-11 | |
| 2019-06-30 | -$2.27M 10-K · filed 2021-03-11 | -$2.26M 10-Q · filed 2019-09-03 | -$4.61M 10-Q · filed 2020-08-10 | -$4.61M 10-Q · filed 2019-09-03 | -$1.75M derived: sum of 3 quarters · filed 2021-03-11 | -$6.20M derived: sum of 4 quarters · filed 2021-03-11 | |
| 2019-03-31 | -$2.34M 10-K · filed 2021-03-11 | $520.00K derived: sum of 2 quarters · filed 2021-03-11 | -$3.94M derived: sum of 3 quarters · filed 2021-03-11 | -$8.02M derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2018-12-31 | $2.86M 10-K · filed 2020-03-10 | -$1.59M derived: sum of 2 quarters · filed 2020-03-10 | -$5.67M derived: sum of 3 quarters · filed 2020-03-10 | -$10.16M 10-K · filed 2020-03-10 | |||
| 2018-09-30 | -$4.46M 10-K · filed 2020-03-10 | -$4.46M 10-Q · filed 2019-11-12 | -$8.54M derived: sum of 2 quarters · filed 2020-03-10 | -$13.02M 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | -$4.08M 10-K · filed 2020-03-10 | -$4.08M 10-Q · filed 2019-09-03 | -$8.57M 10-Q · filed 2019-09-03 | ||||
| 2018-03-31 | -$4.49M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |